Hi
I started a trial for CLL 3 months ago,I am on a trial & started taking zanubrutinib for 3 cycles,I have started to take Sonrotoclax from yesterday as well as zanubrutinib.I had no problems with zanutrinib ,no ill effects at all ,my red blood cells went from 60 to 128 & white cells are considerably down.My haematologist says the added drug will bring my levels back to normal quicker ,Will keep you all informed
👍🏻
this is good to hear - hope things continue well
Thank you👍🏻
Hi! Are you on Phase 3 clinical trial with your zanu and Sonroclax? I’m waiting to hear from Moffitt Cancer Center for my start date for that phase 3 trial!
Good luck!
Hi I started on zanubrutinib 3 months ago,I am now starting Sonrotoclax on a slow ramp up, My results are very promising ,my spleen has returned to normal size & my blood levels both red & white are slowly returning to normal levels,it’s early days yet but looks promising.I have had no side effects at all.Good luck with your treatment
That’s awesome to hear!!! Thanks for participating.
Sonrotoclax, also known as BGB-11417, is a next-generation BCL2 inhibitor developed by BeiGene. It’s designed to be more potent and selective than venetoclax, the currently established BCL2 inhibitor. Sonrotoclax works by mimicking the BH3-only proteins to inhibit BCL2, a protein that helps cancer cells survive.
Clinical trials have shown promising results, particularly when sonrotoclax is combined with zanubrutinib, a second-generation BTK inhibitor. This combination aims to provide a more effective and less toxic treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In these trials, sonrotoclax demonstrated higher potency than venetoclax and had a shorter half-life, allowing for a more flexible dosing schedule .
The ongoing phase 1/2 trials for treatment-naive CLL/SLL patients showed no disease progression or deaths at median follow-ups of around 9.7 months. All patients in these trials responded to the treatment, with 32% achieving complete remission or near-complete remission. Additionally, minimal residual disease (MRD) levels showed significant improvement over time .
Sonrotoclax, when combined with zanubrutinib, aims to improve the standard of care by reducing toxicity compared to previous combinations such as ibrutinib and venetoclax, which were associated with higher adverse event rates .
For more detailed information, you can refer to the articles from the American Journal of Managed Care and CLL Society .
Red blood cells 60? What kind of units do you use? Good luck with the treatment!
The haematologist had me at 60& white count at 600 she said she had never seen figures like this before .reds are now 118 ,whites are dropping past 300, thanks to the treatment,don’t know how they arrive at these figures but as long as the figures are in my favour I’m happy
Some strange numbers indeed.
All I can say is THANK YOU to all our members who help pave the way for new treatments by participating in these drug trials! You are all so appreciated. Best of luck on this journey.
Good luck
Progress update - Pirtobrutinib triple trial for treatment naive 
CLL experience
MRD Negative in the Bone Marrow - clinical trial update
OSU Trial Update Cycle 9, Day 1
